Osteoinduction in human fat derived stem cells by recombinant human bone morphogenetic protein-2 produced in Escherichia coli by Bessa, Paulo C. et al.
ORIGINAL RESEARCH PAPER
Osteoinduction in human fat-derived stem cells by
recombinant human bone morphogenetic
protein-2 produced in Escherichia coli
Paulo C. Bessa Æ A. J. Pedro Æ B. Klo¨sch Æ A. Nobre Æ
M. van Griensven Æ R. L. Reis Æ M. Casal
Received: 10 May 2007 / Revised: 16 July 2007 / Accepted: 17 July 2007
 Springer Science+Business Media B.V. 2007
Abstract Bioactive recombinant human bone
morphogenetic protein-2 (rhBMP-2) was obtained
using Escherichia coli pET-25b expression system:
55 mg purified rhBMP-2 were achieved per g cell dry
wt, with up to 95% purity. In murine C2C12 cell line,
rhBMP-2 induced an increase in the transcription of
Smads and of osteogenic markers Runx2/Cbfa1 and
Osterix, measured by semi-quantitative RT-PCR.
Bioassays performed in human fat-derived stem cells
showed an increased activity of the early osteogenic
marker, alkaline phosphatase, and the absence of
cytotoxicity.
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Introduction
Bone morphogenetic proteins (BMPs) are a group of
cytokines from the TGF-b superfamily (Wozney
et al. 1988) with a strong ability to induce bone and
cartilage formation (Urist 1965; Reddi 1998). BMPs
have been used as powerful osteoinductive compo-
nents in several late-stage tissue engineering products
for bone grafting (Westerhuis et al. 2005).
During the process of bone healing, signals
from BMPs trigger the differentiation of stem
cells into bone-forming cells that are recruited to
the site of injury (Reddi 1981). BMPs bind to serine-
threonine kinase cell receptors and mediate their
signals through Smad-related cascades and Smad-
independent pathways (Derynck 2001; Shi and
Massague 2003). Signal is regulated by different
factors such as binding to cell surface receptors
(Kirsch et al. 2000; Sebald et al. 2004), formation of
BMP-heterodimers (Israel et al. 1996), presence of
antagonists such as Noggin (Groppe et al. 2002),
cross-talk with other pathways (Miyazono et al.
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2005) and the presence of a heparin binding domain
in the N-terminal region of BMP-2 which provides
anchorage of the cytokine to the extracelular matrix
(Ruppert et al. 1996; Kubler et al. 1999; Wurzler
et al. 2004).
Currently, most BMPs are obtained from mam-
malian cell cultures in low yields (Wang et al.
1990; Israel et al. 1992) or from bacteria inclusion
bodies after time-consuming refolding procedures
(Kubler et al. 1998; Vallejo et al. 2002; Long et al.
2006). Aiming to circumvent the disadvantages of
the previously reported methods, we have devel-
oped a novel approach for the production of high
amounts of soluble and pure rhBMP-2, with a
bioactivity verified in murine myoblast C2C12 cell




The sequence coding for the mature (bioactive)
domain of human BMP-2 was obtained from a
bacterial clone (Sanger Institute, UK), containing
locus 20p12.1-13 of chromosome 20 of human
genome, which includes the entire gene for
human BMP-2 (clone ref. RP5-859D4). According
to the data in the Human Genome Project
(http://www.ensembl.org/homo_sapiens), the entire
human BMP-2 gene (Ensembl gene OTT-
HUMG00000031833) includes three exons and two
introns with the open reading frame located on exons
2 and 3. By consulting UniProtKB/Swiss-Prot, human
BMP-2 protein (P12643) mature domain consists of
amino acids 283–396, which is obtained after cleav-
age from propeptide (Hillger et al. 2005). The region
corresponding to the mature domain is located solely
in exon 3 and, for this reason, we have cloned directly
by PCR this sequence from the above mentioned
clone (Fig. 1A). Mature domain was amplified by
PCR using primers 50-CGG GAT CCA CAA GCC
AAA CAC AAA CAGC-30 (forward primer) and
50-CCC TCG AGG CGA CAC CCA CAA CCC
TC-30 (reverse primer). The nucleotides for cleav-
age by BamHI and XhoI in forward primer
and reverse primers, respectively, are underlined
the codons corresponding to amino acids 283
and 396 are represented in bold. PCR-product was
first cloned into pGEM T-Easy vector (Promega,
USA) and then subcloned in a pET-25b vector
(Novagen, USA) via the two restriction sites,
BamHI and XhoI (plasmid pET-25b/rhBMP-2), that
was used to transform E. coli BL21(DE3) strain
(Invitrogen, UK). DNA cloning and manipulation
were performed according to standard protocols
(Sambrook et al. 1989). The integrity of cloned
PCR products was verified by DNA sequencing
(Sanger et al. 1977) using ABI PRISM310 Genetic
Analyzer.
Forward strand DNA  12.60 bp 
Exon1                Exon2                                    Exon3
Signal Propeptide 
1  23  24              282  283                               396
Mature BMP-2 




  T7 Promoter 
Ori
 peIB leader 
BamH I
XhoI
Fig. 1 Strategy used for cloning the mature domain of
human bone morphogenetic protein-2. (A) BMP-2 gene
contains three exons represented by boxes and two introns
corresponding to the lines. Coding region is represented by
black boxes located in exon 2 and 3. The mature domain of
human BMP-2 protein is entirely located on exons 3
correspondent to amino acids 283–396. (B) Construction of
vector pET-25b/rhBMP-2 for expression of human BMP-2
in E. coli. The mature BMP-2 was cloned into the vector
pET-25b together with its own leader sequence and
6-histidine tag for purification
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Expression of rhBMP-2 in E. coli growing
in a bioreactor
Transformed E. coli BL21(DE3) strain with pET-
25b/rhBMP-2 or pET-25b vectors were picked and
transferred into 50 ml Luria Bertani (LB) media with
50 lg ampicillin/ml and incubated at 37C for 1–2 h.
Pre-cultures were then transferred to a pre-autoclaved
2 l Bioflo110 bioreactor (New Brunswick Scientific,
USA) containing LB media with 50 lg ampicillin/ml
and cultured at 37C to an OD600 of 1 when 1 mM
IPTG was then added and temperature lowered to
25C. During the entire process, aeration was kept at
2 l/min and an agitation cascade between 300 rpm
and 1,000 rpm was selected in order to maintain
minimum dissolved oxygen levels at 30% of satura-
tion. The pH 7.4 was kept constant using NH4OH
(30%, v/v) and H3PO4 (5 M) pumped into the
bioreactor vessel. Biomass was collected by centri-
fugation (4,000 g, 20 min, 4C), washed once with
PBS and stored at 20C.
Purification of rhBMP-2
Frozen bacteria were resuspended in lysis buffer
(20 mM sodium phosphate buffer, 0.5 M NaCl,
1 mg/ml lysozyme), with inhibitor of proteases
(Complete Mini EDTA-free, Roche). Bacteria were
ultrasonicated 4 times for 15 s with intervals of 1 min
on ice and supernatant and pellet fractions collected
by centrifugation (4,000 g, 30 min, 4C). The pellet
was then incubated overnight in solubilization buffer
(phosphate/saline buffer, 40 mM imidazole, 0.7 M
L-arginine, pH 11.0) at 18C with gentle stirring and
the supernatant containing soluble rhBMP-2 collected
after centrifugation (4,000 g, 4C, and 30 min). The
supernatant was adjusted to pH 8.5 with 0.1 M HCl
and applied to a pre-equilibrated HisTrap chroma-
tography column (Amersham). Briefly, column was
equilibrated with 5 column volumes of sodium
phosphate buffer containing 40 mM imidazole. The
column was washed extensively with 60–80 ml of
sodium phosphate buffer containing 80 mM imidaz-
ole and sample eluted in 15 ml of sodium phosphate
buffer containing 500 mM imidazole. The flow rate
was 5 ml/min during the whole procedure. Samples
were analyzed by SDS-PAGE and Western blotting.
Imidazole was removed by buffer exchange to
phosphate buffer saline with use of a HiTrap
desalting column (Amersham) prior to bioactivity
tests.
Analytical detection of rhBMP-2 by reducing
and non-reducing SDS-PAGE and Western-blot
Protein samples were mixed with SDS-PAGE loading
buffer and heated at 95C for 5 min. Samples were
separated by using hand-cast 10–12% SDS-PAGE
gels in reducing or non-reducing conditions. Reduc-
ing conditions included the use of SDS-PAGE
loading buffer with 5% (v/v) b-mercaptoethanol as
reducing agent. Coomassie Blue-R or silver staining
was used for visualization and staining of gels.
Samples were then electro-transferred (semi-dry
Western-blot transfer) to a nitrocellulose membrane
at 400 mA, 10 V for 30 min. The membranes were
blocked with 2% (w/v) BSA in PBS-T buffer (PBS,
0.05% Tween 20) and incubated either with perox-
idase conjugated anti-His antibody (Sigma) diluted
1:5,000 or rabbit anti-human BMP-2 polyclonal
primary antibody (AbD Serotec) diluted 1:5,000
followed by mouse anti-rabbit peroxidase conjugated
secondary antibody (Amersham) diluted 1:30,000.
Image detection was performed with ChemiDoc XRS
and Quantity One software (BioRad).
Bioactivity tests
C2C12 cells were seeded at 105 cells/ml per well in a
24-well plate, attached overnight in Dulbecco’s
modified Eagle’s medium (DMEM) with 1% (v/v)
fetal calf serum and no antibiotics, at 37C with 5%
CO2 in a humidified environment. Cells were incu-
bated for 5 days with rhBMP-2 purified by the
method described above and a commercial rhBMP-
2 (Wyeth, USA) used as control. Primary cultures of
human fat tissue derived stem cells (Malafaya et al.
2005; Zuk et al. 2002) were seeded at 105 cells/ml
per well in a 24-well plate and attached overnight
in DMEM with 50 lg ascorbic acid/ml, 10 mM
b-glycerophosphate, 100 U penicillin/ml, 100 lg
streptomycin/ml and 10% (v/v) fetal bovine serum
at 37C in 10% CO2. Cells were incubated for
14 days with rhBMP-2 purified by our method,
with media replacement every 2 days. Alkaline
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phosphatase (ALP) enzymatic activity was
determined accordingly to standard procedures (Sal-
gado et al. 2002) after 5 days on C2C12 cell line
cultures and after 3, 7 and 14 days on cell cultures of
mesenchymal stem cells. MTS cell viability assay
was determined after 3, 7 and 14 days of cell culture
in human stem cells (Salgado et al. 2002). For
RT-PCR, mRNA of C2C12 cells was extracted after
5 days of cell culture with TriReagent RNA Isolation
Reagent (Sigma-Aldrich) and cDNA was synthesized
from 4 lg total RNA with oligo dT primer (MWG
Biotech AG) and AMV reverse transcriptase (Pro-
mega). The polymerase chain reaction (PCR) was
performed with specific primers for osteogenic
markers (Table 1) and with use of a Hot Star Taq
Polymerase (Qiagen). Agarose gels were imaged with
MultiImage Light Cabinet (Alpha Innotech, USA)
and gene expression analyzed with ChemiImage 4400
AlphaEase FC Image Analysis Software (Alpha
Innotech, USA) and using polymerase II for normal-
izing gene expression.
Results
Cloning, expression and purification of rhBMP-2
The PCR gave a single product of the coding region
of human BMP-2, with expected size of 359 bp (data
not shown). DNA sequencing revealed a total
correspondence to the encoded amino acids (Ensembl
gene OTTHUMG00000031833). Figure 1B shows
the map of the expression vector pET-25b/rhBMP-2
used for transformation of bacteria. E. coli BL21
(DE3) strain transformants were grown and collected
in conditions described in Material and Methods
section. After bacteria lysis, rhBMP-2 was found
mainly in the pellet (fraction corresponding to
bacterial debris) (Fig. 2A). Soluble protein was then
recovered with phosphate buffer containing 0.7 M
L-arginine, pH 11.0. Purification procedures revealed
that rhBMP-2 was expressed in monomer, dimer and
polymer forms visible in Western-blot using antibod-
ies anti-histidine tag and anti-BMP-2. Silver stained
SDS-PAGE revealed up to 95% purity (Fig. 2B).
RhBMP-2 stored in 20 mM phosphate sodium, 0.5 M
NaCl was found to be stable over 2 months at pH
range of 7–9 (data not shown).
Biological activity in C2C12 cells
Bioassays were performed in murine myoblast
C2C12 cell line, by the administration of purified
rhBMP-2. Semi-quantitative RT-PCR revealed an
increase of expression of early osteoblast differenti-
ation markers after 5 days of cell culture, such as the
osteochondral transcription factor Runx2/Cbfa1 (by 2
to 3-fold), Smad-1 and -5 (up to 1.5-fold) and osteo-
blast transcription factor Osterix (up to 1.5-fold).
Table 1 Oligonucleotide
primers for semi-quantitative
RT-PCR analysis in murine
C2C12 cells
Gene marker Primer sequence: Sense/Antisense
Runx2/Cbfa1 50-GCC GCA GTG CCC CGA TTG AGG-30
50-AGG GAG GGC CTG GGG TTC TGA GG-30
Smad-1 50-CCC ACC TGC TTA CCT GCC TCC TGA-30
50-TGG GGT GAA AGC CGT GGT GGT AGT-30
Smad-5 50-AAT GGG CAG AAA AGG CAG TGG ATG-30
50-AGC GTT GTT GGG TTG GTG GAA AGA-30
Osterix 50-GCA GTG GGG CAG GGC GTT CTA CC-30
50-GGG GCG GCT GAT TGG CTT CTT CTT-30
Osteocalcin 50-ATT CAT ATG AGG ACC CTC TCT CTG-30
50-ATT AGA TCT CTA ATG ATG ATG ATG
ATG ATG AAT AGT GAT ACC GTA GAT-30
ALP 50-CAC GCG ATG CAA CAC CAC TCA GG-30
50-GCA TGT CCC CGG GCT CAA AGA-30
Polymerase II 50-TAC ACC CCA GCT TCT CCC AAA TAC-30
50-AGC TCT TCG CCC TGT TCG-30
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In these tests, the levels of ALP mRNA did not
changed significantly. Commercial mammalian
rhBMP-2 induced markedly Runx2/Cbfa1 by
3–7-fold, Smad-1 and Smad-5 by 2–5 fold, Osterix
by 2 to 4-fold, Osteocalcin by 2–9-fold and high
levels of ALP expression were detected (Fig. 3).
Biological activity in mesenchymal stem cells
RhBMP-2 did not show any significant evidence of
cytotoxicity in human mesenchymal stem cells after
2 weeks of cell culture (Fig. 4A). MTS is a viability/
proliferation test and an inverse relationship of toxicity
to cells can be assumed. In human primary cultures of
fat-derived stem cells, there was an increase in levels of
ALP enzymatic activity (Fig. 4B). Data correlates with
morphological observations of the cells with optical
microscopy (Fig. 5).
Discussion
A novel and more simple approach has been devel-
oped for the production of readily soluble rhBMP-2
using E. coli that, for the first time, is bioactive in
human cell cultures. In previous reports, recombinant
BMP-2 production was achieved in bacterial inclu-
sion bodies in fairly large amounts (Li et al. 1998;
Vallejo et al. 2002; Long et al. 2005). However,
inclusion bodies require time-consuming steps for
solubilization and refolding. In our approach, we
have achieved expression of rhBMP-2 directly folded
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Fig. 2 (A) Coomassie-blue stained SDS-PAGE of crude
lysates, pellet fraction, from batch cultivation of transformed
E. coli. Lanes 1) pET-25b clone; 2) rhBMP-2/pET-25b clone.
Monomer appears as a well-defined band around 17 kDa.
Molecular weight is in kDa (Broad Range, BioRad).
(B) rhBMP-2 purified by affinity chromatography: 1) Silver
stained reduced SDS-PAGE, showing the monomer of BMP-2
with significant purity; 2) Western-blot using anti-his tag
antibody; 3) Western-blot using anti-BMP-2 antibody. BMP-2
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Fig. 3 RT-PCR for genes involved during osteoblast differ-
entiation of C2C12 cells after 5 days of culture with purified
rhBMP-2 and commercial mammalian rhBMP-2 as control.
Gene expression was analyzed with ChemiImage 4400
AlphaEase FC Image Analysis Software (Alpha Innotech)
and standardized with Polymerase II expression. OSX: osterix;
OC: osteocalcin; ALP: alkaline phosphatase. Conditions used:
1) No rhBMP-2; 2) 250 ng/ml; 3) 500 ng/ml; 4) 1,000 ng/ml;
5) 250 ng/ml commercial preparation; 6) 500 ng/ml commer-
cial preparation; 7) 1,000 ng/ml commercial preparation. Data
presented are mean values of two independent experiments.
(*bioassay was not performed)
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directs production of soluble recombinant protein into
periplasmatic space of E. coli, thus allowing the
formation of disulfide bridges.
Recovery with 0.7 M L-arginine buffer resulted
in monomer, dimer and polymer forms adding
value to what has been reported by Klo¨sch et al.
(2005) and Long et al. (2006). Formation of
cysteine bridges is favored at slightly alkaline pH,
thus increasing amounts of dimeric rhBMP-2 (Val-
lejo and Rinas 2004). However, this contribution
seems to be the first one to show this method to
obtain soluble and dimeric BMP-2 directly upon
production. The amount of purified rhBMP-2 was
about 55 mg per g cell dry wt, corresponding to
110 mg purified rhBMP-2 per liter of culture broth.
In previous studies, recombinant BMPs obtained
from E. coli were tested in murine cells lines C2C12
(Vallejo et al. 2002; Long et al. 2006), MC3T3-E1
(Klo¨sch et al. 2005) and CH310T1/2 (Yang et al. 2003)
or in vivo rodent models (Kubler et al. 1998; Bessho
et al. 2000; Hillger et al. 2005). In our case, bioactivity
was achieved using primary cultures of human stem
cells. Binding of active BMP-2 to cell receptors results in
an increase of early markers activated during osteogenic
differentiation (i.e., Runx2, Osterix). In human stem
cells, rhBMP-2 increased ALP activity and differentiated
cells into osteoblast-like morphology. In conclusion, the
novel approach described herein shows steps for
improving the production of high amounts of readily
soluble rhBMP-2 that shows bioactivity in primary
human adult stem cells, and can be use for diverse bone
tissue engineering research applications.
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